FDA Approves Orgovyx for Advanced Prostate Cancer Treatment

The FDA has approved the oral gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix (Orgovyx) as a treatment for patients with advanced prostate cancer.

The FDA has approved the oral gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix (Orgovyx) as a treatment for patients with advanced prostate cancer.1

The regulatory decision was based on data from the pivotal phase 3 HERO trial, where relugolix showcased superiority over leuprolide (Lupron) in terms of sustained testosterone (T)-suppression through 48 weeks, fast T-recovery following discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced disease.2,3

In the international, 48-week, phase 3 trial, a total of 934 patients with androgen-sensitive advanced prostate cancer were randomized in a 2:1 fashion to either oral relugolix at a once-daily dose of 120 mg following a one-time 360 mg loading dose (n = 624) or a 3-month depot injection of leuprolide acetate (n = 310). In a subset of 184 patients, investigators examined testosterone recovery.

To be eligible for enrollment, patients to have confirmed advanced prostate cancer, have received at least 1 year of androgen deprivation therapy (ADT), a serum prostate-specific antigen higher than 2.0 ng/mL, and an ECOG performance status of either 0 or 1.

If patients were expected to receive chemotherapy or undergo surgery within 2 months of ADT administration, had previous ADT for longer than 18 months for prior systemic cytotoxic treatment for their disease, had active liver disease, or severe cardiovascular risk conditions, they were excluded from the trial.

A total of 563 patients who received relugolix completed treatment versus 276 patients who received leuprolide. Additionally, 9.5% of patients in the investigational arm versus 10.3% in the control arm discontinued treatment early. The remaining participants underwent randomization but they did not receive treatment.

Baseline characteristics were found to be balanced between the arms. Approximately 50% of patients who enrolled on the trial experienced biochemical recurrence following definitive treatment for prostate cancer. Moreover, 28.9% of patients were enrolled in North America and 11.5% were enrolled in Japan. Almost all patients, or over 90%, had at least 1 cardiovascular risk factor.

Additional data demonstrated that 96.7% (95% CI, 94.9%-97.9%) of patients who were given relugolix achieved and maintained castration through 48 weeks compared with 88.8% of those who received leuprolide. The 7.9%-difference (95% CI, 4.1%-11.8%) showed noninferiority (margin — 10%) and superiority (P <.0001) of relugolix to leuprolide. Notably, all secondary end points evaluated also showcased superiority for relugolix over leuprolide (P <.0001).

In those who were assessed for testosterone recovery, median T-levels in the relugolix and leuprolide arms were 270.76 ng/dL and 12.26 ng/dL, respectively, 90 days following discontinuation of treatment.

Updated data from HERO showed that relugolix was not found to achieve statistical superiority with regard to castration resistance—free survival compared with leuprolide through 48 weeks in this population.4 Specifically, 74% of patients with metastatic disease in the relugolix arm were castration resistance free in this time period versus 75% of those in the leuprolide arm (HR, 1.03; 95% CI, 0.68-1.57; P = .84).

With regard to safety, MACE incidence was found to be lower in the investigational arm versus the control arm, at 2.9% versus 6.2%, respectively. The rest of the profiles of the 2 agents proved to be comparable with the exception of that factor.

Specifically, toxicities experienced by more than 10% of patients who received relugolix or leuprolide included hot flash (54.3% vs 51.6%, respectively), fatigue (21.5% vs 18.5%), constipation (12.2% vs 9.7%), diarrhea (12.2% vs 6.8%), arthralgia (12.1% vs 9.1%), and hypertension (7.9% vs 11.7%). Diarrhea reported on the trial was only grade 1 or 2 and did not lead to treatment discontinuation.

References

1. FDA approves first oral hormone therapy for treating advanced prostate cancer. News release. FDA. December 18, 2020. Accessed December 18, 2020. http://bit.ly/2Ws5nvz.

2. Shore ND, George DJ, Saad F, et al. HERO phase III trial: results comparing relugolix, an oral GnRH receptor antagonist versus leuprolide acetate for advanced prostate cancer. J Clin Oncol. 2020;38(suppl 15):5602. doi:10.1200/JCO.2020.38.15_suppl.5602

3. Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187-2196. doi:10.1056/NEJMoa2004325

4. Myovant Sciences announces results of additional secondary endpoint of castration resistance-free survival from phase 3 HERO study of relugolix in advanced prostate cancer. News release. Myovant Sciences. September 29, 2020. Accessed December 3, 2020. https://bit.ly/3cFMooy.

This article was originally published on OncLive.